BG63121B1 - Таксоиди, тяхното получаване и фармацевтични състави, които ги съдържат - Google Patents

Info

Publication number

BG63121B1

BG63121B1 BG101918A BG10191897A BG63121B1 BG 63121 B1 BG63121 B1 BG 63121B1 BG 101918 A BG101918 A BG 101918A BG 10191897 A BG10191897 A BG 10191897A BG 63121 B1 BG63121 B1 BG 63121B1

Authority

BG

Bulgaria

Prior art keywords

radical

oddc

carbon atoms

cancer

general formula

Prior art date

1995-03-27

Links

• Espacenet
• Global Dossier
• Discuss

• 238000002360 preparation method Methods 0.000 title claims description 28
• 239000008194 pharmaceutical composition Substances 0.000 title claims description 11
• -1 bicycloalkyl radical Chemical class 0.000 claims abstract description 280
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 58
• 125000000217 alkyl group Chemical group 0.000 claims abstract description 51
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 35
• CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims abstract description 28
• 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 12
• 230000000259 anti-tumor effect Effects 0.000 claims abstract description 9
• LEVJVKGPFAQPOI-UHFFFAOYSA-N phenylmethanone Chemical class O=[C]C1=CC=CC=C1 LEVJVKGPFAQPOI-UHFFFAOYSA-N 0.000 claims abstract description 9
• 125000003342 alkenyl group Chemical group 0.000 claims abstract description 8
• 125000000304 alkynyl group Chemical group 0.000 claims abstract description 5
• 125000004432 carbon atom Chemical group C* 0.000 claims description 159
• 206010028980 Neoplasm Diseases 0.000 claims description 116
• 150000003254 radicals Chemical class 0.000 claims description 99
• 239000000126 substance Substances 0.000 claims description 96
• 150000001875 compounds Chemical class 0.000 claims description 83
• 210000004027 cell Anatomy 0.000 claims description 74
• 239000000203 mixture Substances 0.000 claims description 53
• 238000011282 treatment Methods 0.000 claims description 53
• 239000003795 chemical substances by application Substances 0.000 claims description 51
• 238000000034 method Methods 0.000 claims description 50
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 46
• 150000003839 salts Chemical class 0.000 claims description 44
• 125000006239 protecting group Chemical group 0.000 claims description 32
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
• 239000000243 solution Substances 0.000 claims description 29
• 239000000047 product Substances 0.000 claims description 28
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 26
• 125000005843 halogen group Chemical group 0.000 claims description 26
• 230000009471 action Effects 0.000 claims description 23
• 230000000694 effects Effects 0.000 claims description 23
• 239000002253 acid Substances 0.000 claims description 21
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
• 150000002148 esters Chemical group 0.000 claims description 19
• 229910052757 nitrogen Inorganic materials 0.000 claims description 19
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
• 125000004429 atom Chemical group 0.000 claims description 18
• 239000003814 drug Substances 0.000 claims description 18
• 239000003960 organic solvent Substances 0.000 claims description 17
• 238000006467 substitution reaction Methods 0.000 claims description 17
• 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 16
• 238000003756 stirring Methods 0.000 claims description 16
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
• 125000002252 acyl group Chemical group 0.000 claims description 15
• 229910052739 hydrogen Inorganic materials 0.000 claims description 15
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 14
• 230000002159 abnormal effect Effects 0.000 claims description 14
• 238000006243 chemical reaction Methods 0.000 claims description 14
• 229940079593 drug Drugs 0.000 claims description 14
• 241000699670 Mus sp. Species 0.000 claims description 13
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
• 239000002585 base Substances 0.000 claims description 12
• 229910052799 carbon Inorganic materials 0.000 claims description 12
• 239000000460 chlorine Substances 0.000 claims description 12
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
• 229910052760 oxygen Inorganic materials 0.000 claims description 11
• 239000001301 oxygen Substances 0.000 claims description 11
• 108090000623 proteins and genes Proteins 0.000 claims description 11
• 239000011541 reaction mixture Substances 0.000 claims description 11
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
• 230000004663 cell proliferation Effects 0.000 claims description 10
• 239000003085 diluting agent Substances 0.000 claims description 10
• 239000001257 hydrogen Substances 0.000 claims description 10
• 238000001727 in vivo Methods 0.000 claims description 10
• 238000012360 testing method Methods 0.000 claims description 10
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 10
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 9
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 9
• 239000000706 filtrate Substances 0.000 claims description 9
• 229910052731 fluorine Inorganic materials 0.000 claims description 9
• 125000001424 substituent group Chemical group 0.000 claims description 9
• 238000002560 therapeutic procedure Methods 0.000 claims description 9
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
• 239000000654 additive Substances 0.000 claims description 8
• 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 8
• 125000003118 aryl group Chemical group 0.000 claims description 8
• 150000005840 aryl radicals Chemical class 0.000 claims description 8
• 229910052801 chlorine Inorganic materials 0.000 claims description 8
• 230000014509 gene expression Effects 0.000 claims description 8
• 125000005842 heteroatom Chemical group 0.000 claims description 8
• 239000000741 silica gel Substances 0.000 claims description 8
• 229910002027 silica gel Inorganic materials 0.000 claims description 8
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 7
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
• 125000003545 alkoxy group Chemical group 0.000 claims description 7
• 239000002246 antineoplastic agent Substances 0.000 claims description 7
• 230000032050 esterification Effects 0.000 claims description 7
• 238000005886 esterification reaction Methods 0.000 claims description 7
• ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims description 7
• 238000000338 in vitro Methods 0.000 claims description 7
• 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
• 235000010755 mineral Nutrition 0.000 claims description 7
• 239000011707 mineral Substances 0.000 claims description 7
• 150000007524 organic acids Chemical class 0.000 claims description 7
• 230000035755 proliferation Effects 0.000 claims description 7
• 238000001228 spectrum Methods 0.000 claims description 7
• 229910052717 sulfur Inorganic materials 0.000 claims description 7
• 239000011593 sulfur Chemical group 0.000 claims description 7
• 230000001225 therapeutic effect Effects 0.000 claims description 7
• 210000001519 tissue Anatomy 0.000 claims description 7
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
• 208000026310 Breast neoplasm Diseases 0.000 claims description 6
• 206010025323 Lymphomas Diseases 0.000 claims description 6
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
• 201000010099 disease Diseases 0.000 claims description 6
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
• 150000002170 ethers Chemical class 0.000 claims description 6
• 239000011737 fluorine Substances 0.000 claims description 6
• 239000011521 glass Substances 0.000 claims description 6
• 238000001990 intravenous administration Methods 0.000 claims description 6
• 150000002825 nitriles Chemical class 0.000 claims description 6
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
• 229920006395 saturated elastomer Polymers 0.000 claims description 6
• 239000011780 sodium chloride Substances 0.000 claims description 6
• KKFDJZZADQONDE-UHFFFAOYSA-N (hydridonitrato)hydroxidocarbon(.) Chemical compound O[C]=N KKFDJZZADQONDE-UHFFFAOYSA-N 0.000 claims description 5
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 5
• 241000282412 Homo Species 0.000 claims description 5
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 5
• 206010033128 Ovarian cancer Diseases 0.000 claims description 5
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
• 150000003973 alkyl amines Chemical class 0.000 claims description 5
• 150000001412 amines Chemical class 0.000 claims description 5
• 230000000340 anti-metabolite Effects 0.000 claims description 5
• 229940100197 antimetabolite Drugs 0.000 claims description 5
• 239000002256 antimetabolite Substances 0.000 claims description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
• 210000000481 breast Anatomy 0.000 claims description 5
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
• 239000006260 foam Substances 0.000 claims description 5
• 239000000499 gel Substances 0.000 claims description 5
• 201000001441 melanoma Diseases 0.000 claims description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
• 238000011321 prophylaxis Methods 0.000 claims description 5
• 239000002904 solvent Substances 0.000 claims description 5
• 239000000725 suspension Substances 0.000 claims description 5
• 239000003826 tablet Substances 0.000 claims description 5
• YWLXLRUDGLRYDR-SKXCCXORSA-N 10-dab iii Chemical compound O([C@H]1C2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-SKXCCXORSA-N 0.000 claims description 4
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
• 150000001298 alcohols Chemical class 0.000 claims description 4
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
• 125000004414 alkyl thio group Chemical group 0.000 claims description 4
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
• PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 claims description 4
• 230000004071 biological effect Effects 0.000 claims description 4
• 229910052794 bromium Inorganic materials 0.000 claims description 4
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
• 239000003153 chemical reaction reagent Substances 0.000 claims description 4
• 229940127089 cytotoxic agent Drugs 0.000 claims description 4
• 125000005265 dialkylamine group Chemical group 0.000 claims description 4
• 229960002949 fluorouracil Drugs 0.000 claims description 4
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
• 210000004072 lung Anatomy 0.000 claims description 4
• 230000003211 malignant effect Effects 0.000 claims description 4
• 229960000485 methotrexate Drugs 0.000 claims description 4
• 210000000496 pancreas Anatomy 0.000 claims description 4
• 239000006187 pill Substances 0.000 claims description 4
• WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
• 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims description 4
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
• WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical group [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 claims description 3
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
• 125000005118 N-alkylcarbamoyl group Chemical group 0.000 claims description 3
• 201000004681 Psoriasis Diseases 0.000 claims description 3
• 230000003213 activating effect Effects 0.000 claims description 3
• 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 3
• 239000003242 anti bacterial agent Substances 0.000 claims description 3
• 150000004982 aromatic amines Chemical class 0.000 claims description 3
• 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 3
• 125000004104 aryloxy group Chemical group 0.000 claims description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
• 239000000969 carrier Substances 0.000 claims description 3
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
• 229960004316 cisplatin Drugs 0.000 claims description 3
• 229960000684 cytarabine Drugs 0.000 claims description 3
• 125000002541 furyl group Chemical group 0.000 claims description 3
• 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
• 230000002401 inhibitory effect Effects 0.000 claims description 3
• 239000007788 liquid Substances 0.000 claims description 3
• 150000007522 mineralic acids Chemical class 0.000 claims description 3
• 229930014626 natural product Natural products 0.000 claims description 3
• 239000003921 oil Substances 0.000 claims description 3
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
• 210000002307 prostate Anatomy 0.000 claims description 3
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
• 238000001959 radiotherapy Methods 0.000 claims description 3
• 230000004044 response Effects 0.000 claims description 3
• 125000004434 sulfur atom Chemical group 0.000 claims description 3
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
• 108010006654 Bleomycin Proteins 0.000 claims description 2
• 108010092160 Dactinomycin Proteins 0.000 claims description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
• 102000014150 Interferons Human genes 0.000 claims description 2
• 108010050904 Interferons Proteins 0.000 claims description 2
• 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
• 150000001242 acetic acid derivatives Chemical class 0.000 claims description 2
• 230000010933 acylation Effects 0.000 claims description 2
• 238000005917 acylation reaction Methods 0.000 claims description 2
• 229940088710 antibiotic agent Drugs 0.000 claims description 2
• 239000012736 aqueous medium Substances 0.000 claims description 2
• 239000007864 aqueous solution Substances 0.000 claims description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
• 229960001561 bleomycin Drugs 0.000 claims description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 2
• 125000001589 carboacyl group Chemical group 0.000 claims description 2
• 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims description 2
• 230000003197 catalytic effect Effects 0.000 claims description 2
• 230000001684 chronic effect Effects 0.000 claims description 2
• 239000003086 colorant Substances 0.000 claims description 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
• 229960000975 daunorubicin Drugs 0.000 claims description 2
• 125000005117 dialkylcarbamoyl group Chemical group 0.000 claims description 2
• 229960005420 etoposide Drugs 0.000 claims description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
• 230000001747 exhibiting effect Effects 0.000 claims description 2
• 239000000284 extract Substances 0.000 claims description 2
• 239000008103 glucose Substances 0.000 claims description 2
• 229940047124 interferons Drugs 0.000 claims description 2
• 210000004185 liver Anatomy 0.000 claims description 2
• 229960002247 lomustine Drugs 0.000 claims description 2
• 238000005259 measurement Methods 0.000 claims description 2
• 230000007246 mechanism Effects 0.000 claims description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 2
• 229960001428 mercaptopurine Drugs 0.000 claims description 2
• 229910052751 metal Inorganic materials 0.000 claims description 2
• 239000002184 metal Substances 0.000 claims description 2
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
• GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 2
• 229910052759 nickel Inorganic materials 0.000 claims description 2
• UJRJCSCBZXLGKF-UHFFFAOYSA-N nickel rhenium Chemical class [Ni].[Re] UJRJCSCBZXLGKF-UHFFFAOYSA-N 0.000 claims description 2
• 239000003755 preservative agent Substances 0.000 claims description 2
• 210000002966 serum Anatomy 0.000 claims description 2
• 210000003491 skin Anatomy 0.000 claims description 2
• 238000007920 subcutaneous administration Methods 0.000 claims description 2
• 229960001603 tamoxifen Drugs 0.000 claims description 2
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims description 2
• 229960003087 tioguanine Drugs 0.000 claims description 2
• 229960003048 vinblastine Drugs 0.000 claims description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
• 229960004528 vincristine Drugs 0.000 claims description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
• 238000005406 washing Methods 0.000 claims description 2
• 229910052725 zinc Inorganic materials 0.000 claims description 2
• 239000011701 zinc Substances 0.000 claims description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 76
• 201000011510 cancer Diseases 0.000 claims 37
• 229940104302 cytosine Drugs 0.000 claims 36
• 108091034117 Oligonucleotide Proteins 0.000 claims 15
• 241001465754 Metazoa Species 0.000 claims 13
• 150000002632 lipids Chemical class 0.000 claims 13
• 239000002777 nucleoside Substances 0.000 claims 13
• 208000032839 leukemia Diseases 0.000 claims 12
• 239000007787 solid Substances 0.000 claims 12
• 230000001093 anti-cancer Effects 0.000 claims 11
• 239000003937 drug carrier Substances 0.000 claims 10
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
• 230000001413 cellular effect Effects 0.000 claims 8
• 150000003833 nucleoside derivatives Chemical class 0.000 claims 8
• 230000008569 process Effects 0.000 claims 8
• 230000035945 sensitivity Effects 0.000 claims 8
• 108020004414 DNA Proteins 0.000 claims 7
• 230000004083 survival effect Effects 0.000 claims 7
• 210000004881 tumor cell Anatomy 0.000 claims 7
• WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 6
• 206010009944 Colon cancer Diseases 0.000 claims 6
• 108700020796 Oncogene Proteins 0.000 claims 6
• 208000029742 colonic neoplasm Diseases 0.000 claims 6
• OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 claims 6
• 230000012010 growth Effects 0.000 claims 6
• 238000004519 manufacturing process Methods 0.000 claims 6
• 235000020357 syrup Nutrition 0.000 claims 6
• 239000006188 syrup Substances 0.000 claims 6
• 206010006187 Breast cancer Diseases 0.000 claims 5
• 102000004190 Enzymes Human genes 0.000 claims 5
• 108090000790 Enzymes Proteins 0.000 claims 5
• WQZGKKKJIJFFOK-ZZWDRFIYSA-N L-glucose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-ZZWDRFIYSA-N 0.000 claims 5
• 241000699666 Mus <mouse, genus> Species 0.000 claims 5
• 102000043276 Oncogene Human genes 0.000 claims 5
• 206010060862 Prostate cancer Diseases 0.000 claims 5
• 239000004480 active ingredient Substances 0.000 claims 5
• 229940100198 alkylating agent Drugs 0.000 claims 5
• 239000002168 alkylating agent Substances 0.000 claims 5
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 5
• 230000015556 catabolic process Effects 0.000 claims 5
• 238000006731 degradation reaction Methods 0.000 claims 5
• 239000000463 material Substances 0.000 claims 5
• 108010068698 spleen exonuclease Proteins 0.000 claims 5
• 231100000331 toxic Toxicity 0.000 claims 5
• 230000002588 toxic effect Effects 0.000 claims 5
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 4
• 230000006820 DNA synthesis Effects 0.000 claims 4
• 108060002716 Exonuclease Proteins 0.000 claims 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 4
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 4
• 230000000711 cancerogenic effect Effects 0.000 claims 4
• 239000002775 capsule Substances 0.000 claims 4
• 231100000315 carcinogenic Toxicity 0.000 claims 4
• 210000001072 colon Anatomy 0.000 claims 4
• 239000002552 dosage form Substances 0.000 claims 4
• 102000013165 exonuclease Human genes 0.000 claims 4
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 4
• 201000005202 lung cancer Diseases 0.000 claims 4
• 208000020816 lung neoplasm Diseases 0.000 claims 4
• 238000013160 medical therapy Methods 0.000 claims 4
• GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 4
• 230000004048 modification Effects 0.000 claims 4
• 238000012986 modification Methods 0.000 claims 4
• 150000007523 nucleic acids Chemical class 0.000 claims 4
• 229940127073 nucleoside analogue Drugs 0.000 claims 4
• 230000003287 optical effect Effects 0.000 claims 4
• 239000008177 pharmaceutical agent Substances 0.000 claims 4
• 230000010076 replication Effects 0.000 claims 4
• 239000000758 substrate Substances 0.000 claims 4
• FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 claims 4
• 239000001226 triphosphate Substances 0.000 claims 4
• 235000011178 triphosphate Nutrition 0.000 claims 4
• 230000004614 tumor growth Effects 0.000 claims 4
• IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 claims 3
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
• 102100026846 Cytidine deaminase Human genes 0.000 claims 3
• 108010031325 Cytidine deaminase Proteins 0.000 claims 3
• 102000053602 DNA Human genes 0.000 claims 3
• 239000002841 Lewis acid Substances 0.000 claims 3
• 241000699660 Mus musculus Species 0.000 claims 3
• 241000872931 Myoporum sandwicense Species 0.000 claims 3
• 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 3
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 3
• 150000008064 anhydrides Chemical class 0.000 claims 3
• 239000000074 antisense oligonucleotide Substances 0.000 claims 3
• 238000012230 antisense oligonucleotides Methods 0.000 claims 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 3
• 230000015572 biosynthetic process Effects 0.000 claims 3
• 230000010261 cell growth Effects 0.000 claims 3
• 239000012230 colorless oil Substances 0.000 claims 3
• 150000002009 diols Chemical class 0.000 claims 3
• 235000019439 ethyl acetate Nutrition 0.000 claims 3
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
• 230000005764 inhibitory process Effects 0.000 claims 3
• 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 claims 3
• 239000010410 layer Substances 0.000 claims 3
• 150000007517 lewis acids Chemical class 0.000 claims 3
• 230000000670 limiting effect Effects 0.000 claims 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
• 108020004707 nucleic acids Proteins 0.000 claims 3
• 102000039446 nucleic acids Human genes 0.000 claims 3
• 125000003835 nucleoside group Chemical group 0.000 claims 3
• 239000002773 nucleotide Substances 0.000 claims 3
• 125000003729 nucleotide group Chemical group 0.000 claims 3
• 238000011580 nude mouse model Methods 0.000 claims 3
• 230000003647 oxidation Effects 0.000 claims 3
• 238000007254 oxidation reaction Methods 0.000 claims 3
• 229920005989 resin Polymers 0.000 claims 3
• 239000011347 resin Substances 0.000 claims 3
• 238000010898 silica gel chromatography Methods 0.000 claims 3
• 238000001356 surgical procedure Methods 0.000 claims 3
• 231100000419 toxicity Toxicity 0.000 claims 3
• 230000001988 toxicity Effects 0.000 claims 3
• 230000014616 translation Effects 0.000 claims 3
• UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 3
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims 2
• CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 claims 2
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 2
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
• 201000004384 Alopecia Diseases 0.000 claims 2
• 206010059313 Anogenital warts Diseases 0.000 claims 2
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 2
• 201000009030 Carcinoma Diseases 0.000 claims 2
• 208000000907 Condylomata Acuminata Diseases 0.000 claims 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
• 108010042407 Endonucleases Proteins 0.000 claims 2
• 102000004533 Endonucleases Human genes 0.000 claims 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 2
• 108010010803 Gelatin Proteins 0.000 claims 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
• 206010020649 Hyperkeratosis Diseases 0.000 claims 2
• 206010027476 Metastases Diseases 0.000 claims 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
• IJCKBIINTQEGLY-UHFFFAOYSA-N N(4)-acetylcytosine Chemical compound CC(=O)NC1=CC=NC(=O)N1 IJCKBIINTQEGLY-UHFFFAOYSA-N 0.000 claims 2
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
• SZCXQGFTQXICBU-UHFFFAOYSA-N OC1COC(O)(O)O1 Chemical compound OC1COC(O)(O)O1 SZCXQGFTQXICBU-UHFFFAOYSA-N 0.000 claims 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
• 230000018199 S phase Effects 0.000 claims 2
• 229930006000 Sucrose Natural products 0.000 claims 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
• 241000700605 Viruses Species 0.000 claims 2
• 208000000260 Warts Diseases 0.000 claims 2
• 206010000210 abortion Diseases 0.000 claims 2
• 231100000176 abortion Toxicity 0.000 claims 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
• 239000000783 alginic acid Substances 0.000 claims 2
• 235000010443 alginic acid Nutrition 0.000 claims 2
• 229920000615 alginic acid Polymers 0.000 claims 2
• 229960001126 alginic acid Drugs 0.000 claims 2
• 150000004781 alginic acids Chemical class 0.000 claims 2
• 150000008051 alkyl sulfates Chemical class 0.000 claims 2
• 125000003277 amino group Chemical group 0.000 claims 2
• 208000025009 anogenital human papillomavirus infection Diseases 0.000 claims 2
• 201000004201 anogenital venereal wart Diseases 0.000 claims 2
• 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
• 230000001028 anti-proliverative effect Effects 0.000 claims 2
• 235000010323 ascorbic acid Nutrition 0.000 claims 2
• 229960005070 ascorbic acid Drugs 0.000 claims 2
• 239000011668 ascorbic acid Substances 0.000 claims 2
• 229960002756 azacitidine Drugs 0.000 claims 2
• 239000011230 binding agent Substances 0.000 claims 2
• 230000037396 body weight Effects 0.000 claims 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
• 150000001721 carbon Chemical group 0.000 claims 2
• 238000002512 chemotherapy Methods 0.000 claims 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
• 230000000295 complement effect Effects 0.000 claims 2
• 239000012043 crude product Substances 0.000 claims 2
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 2
• 230000001086 cytosolic effect Effects 0.000 claims 2
• 239000001177 diphosphate Substances 0.000 claims 2
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 2
• 235000011180 diphosphates Nutrition 0.000 claims 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 2
• 239000000975 dye Substances 0.000 claims 2
• 238000005516 engineering process Methods 0.000 claims 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
• 238000002474 experimental method Methods 0.000 claims 2
• 238000001914 filtration Methods 0.000 claims 2
• 239000000796 flavoring agent Substances 0.000 claims 2
• 235000003599 food sweetener Nutrition 0.000 claims 2
• 239000008273 gelatin Substances 0.000 claims 2
• 229920000159 gelatin Polymers 0.000 claims 2
• 229940014259 gelatin Drugs 0.000 claims 2
• 235000019322 gelatine Nutrition 0.000 claims 2
• 235000011852 gelatine desserts Nutrition 0.000 claims 2
• 239000003102 growth factor Substances 0.000 claims 2
• 230000009036 growth inhibition Effects 0.000 claims 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
• 150000002367 halogens Chemical group 0.000 claims 2
• 201000010536 head and neck cancer Diseases 0.000 claims 2
• 208000014829 head and neck neoplasm Diseases 0.000 claims 2
• FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 claims 2
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
• 229940125697 hormonal agent Drugs 0.000 claims 2
• 206010021198 ichthyosis Diseases 0.000 claims 2
• 230000000977 initiatory effect Effects 0.000 claims 2
• 230000009545 invasion Effects 0.000 claims 2
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
• 210000000265 leukocyte Anatomy 0.000 claims 2
• 208000014018 liver neoplasm Diseases 0.000 claims 2
• 231100000053 low toxicity Toxicity 0.000 claims 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
• 230000004060 metabolic process Effects 0.000 claims 2
• NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 claims 2
• CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 claims 2
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
• 229960000907 methylthioninium chloride Drugs 0.000 claims 2
• 230000035772 mutation Effects 0.000 claims 2
• 239000012044 organic layer Substances 0.000 claims 2
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 2
• 210000001672 ovary Anatomy 0.000 claims 2
• 125000004043 oxo group Chemical group O=* 0.000 claims 2
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
• 239000002953 phosphate buffered saline Substances 0.000 claims 2
• 230000003389 potentiating effect Effects 0.000 claims 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
• 102000004169 proteins and genes Human genes 0.000 claims 2
• 230000005855 radiation Effects 0.000 claims 2
• 238000011160 research Methods 0.000 claims 2
• 238000012163 sequencing technique Methods 0.000 claims 2
• 208000017520 skin disease Diseases 0.000 claims 2
• 239000005720 sucrose Substances 0.000 claims 2
• 238000009495 sugar coating Methods 0.000 claims 2
• 239000003765 sweetening agent Substances 0.000 claims 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
• 230000000699 topical effect Effects 0.000 claims 2
• 238000013518 transcription Methods 0.000 claims 2
• 230000035897 transcription Effects 0.000 claims 2
• 238000013519 translation Methods 0.000 claims 2
• 125000004665 trialkylsilyl group Chemical group 0.000 claims 2
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
• 210000003932 urinary bladder Anatomy 0.000 claims 2
• ZVAFCKLQJCZGAP-WDEREUQCSA-N (2r,3s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H]([C@@H](O)C(O)=O)C1=CC=CC=C1 ZVAFCKLQJCZGAP-WDEREUQCSA-N 0.000 claims 1
• UCKYOOZPSJFJIZ-FMDGEEDCSA-N (4r)-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 UCKYOOZPSJFJIZ-FMDGEEDCSA-N 0.000 claims 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
• UXTFKIJKRJJXNV-UHFFFAOYSA-N 1-$l^{1}-oxidanylethanone Chemical compound CC([O])=O UXTFKIJKRJJXNV-UHFFFAOYSA-N 0.000 claims 1
• PJXVQPWEQYWHRL-UHFFFAOYSA-N 1-acetyl-4-aminopyrimidin-2-one Chemical compound CC(=O)N1C=CC(N)=NC1=O PJXVQPWEQYWHRL-UHFFFAOYSA-N 0.000 claims 1
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims 1
• CCZMQYGSXWZFKI-UHFFFAOYSA-N 1-chloro-4-dichlorophosphoryloxybenzene Chemical compound ClC1=CC=C(OP(Cl)(Cl)=O)C=C1 CCZMQYGSXWZFKI-UHFFFAOYSA-N 0.000 claims 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 1
• NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 claims 1
• YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims 1
• OZUCDJFMALKZOS-UHFFFAOYSA-N 2-(butoxycarbonylamino)-2-hydroxy-3-phenylpropanoic acid Chemical group CCCCOC(=O)NC(O)(C(O)=O)CC1=CC=CC=C1 OZUCDJFMALKZOS-UHFFFAOYSA-N 0.000 claims 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 1
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
• KIHAGWUUUHJRMS-JOCHJYFZSA-N 2-octadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@H](CO)COP(O)(=O)OCCN KIHAGWUUUHJRMS-JOCHJYFZSA-N 0.000 claims 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
• LULAYUGMBFYYEX-UHFFFAOYSA-M 3-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-M 0.000 claims 1
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
• ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 claims 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
• GQGVBSHMRYHBTF-UOWFLXDJSA-N 4-amino-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 GQGVBSHMRYHBTF-UOWFLXDJSA-N 0.000 claims 1
• CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical class O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 claims 1
• RXRGZNYSEHTMHC-UHFFFAOYSA-N 4-amino-1-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1C1OC(CO)OC1 RXRGZNYSEHTMHC-UHFFFAOYSA-N 0.000 claims 1
• NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
• 208000030507 AIDS Diseases 0.000 claims 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
• 241000416162 Astragalus gummifer Species 0.000 claims 1
• 208000012526 B-cell neoplasm Diseases 0.000 claims 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
• 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 claims 1
• 239000005711 Benzoic acid Substances 0.000 claims 1
• 241000283690 Bos taurus Species 0.000 claims 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 claims 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
• 241000282472 Canis lupus familiaris Species 0.000 claims 1
• 229920006051 Capron® Polymers 0.000 claims 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
• 206010008342 Cervix carcinoma Diseases 0.000 claims 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
• 102000008186 Collagen Human genes 0.000 claims 1
• 108010035532 Collagen Proteins 0.000 claims 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
• 229920002261 Corn starch Polymers 0.000 claims 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
• 108010036949 Cyclosporine Proteins 0.000 claims 1
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims 1
• 229940123974 Cytidine deaminase inhibitor Drugs 0.000 claims 1
• 108020001019 DNA Primers Proteins 0.000 claims 1
• 239000003155 DNA primer Substances 0.000 claims 1
• 230000033616 DNA repair Effects 0.000 claims 1
• 108010033174 Deoxycytidine kinase Proteins 0.000 claims 1
• 102100029588 Deoxycytidine kinase Human genes 0.000 claims 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
• 206010012735 Diarrhoea Diseases 0.000 claims 1
• 241000283086 Equidae Species 0.000 claims 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
• 208000036566 Erythroleukaemia Diseases 0.000 claims 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
• WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 claims 1
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
• 241000700721 Hepatitis B virus Species 0.000 claims 1
• 101000917383 Homo sapiens Deoxycytidine kinase Proteins 0.000 claims 1
• 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims 1
• 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims 1
• 101001116388 Homo sapiens Melatonin-related receptor Proteins 0.000 claims 1
• 241000725303 Human immunodeficiency virus Species 0.000 claims 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
• 229930010555 Inosine Natural products 0.000 claims 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 1
• 102000015696 Interleukins Human genes 0.000 claims 1
• 108010063738 Interleukins Proteins 0.000 claims 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
• 102100020870 La-related protein 6 Human genes 0.000 claims 1
• 108050008265 La-related protein 6 Proteins 0.000 claims 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
• 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
• 241000124008 Mammalia Species 0.000 claims 1
• 244000246386 Mentha pulegium Species 0.000 claims 1
• 235000016257 Mentha pulegium Nutrition 0.000 claims 1
• 235000004357 Mentha x piperita Nutrition 0.000 claims 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
• 229930192392 Mitomycin Natural products 0.000 claims 1
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
• 235000021360 Myristic acid Nutrition 0.000 claims 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
• 108091093105 Nuclear DNA Proteins 0.000 claims 1
• 108020005497 Nuclear hormone receptor Proteins 0.000 claims 1
• 101710163270 Nuclease Proteins 0.000 claims 1
• 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
• 206010030113 Oedema Diseases 0.000 claims 1
• 229910019142 PO4 Inorganic materials 0.000 claims 1
• 235000021314 Palmitic acid Nutrition 0.000 claims 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
• 102000003992 Peroxidases Human genes 0.000 claims 1
• 208000012641 Pigmentation disease Diseases 0.000 claims 1
• 229920002732 Polyanhydride Polymers 0.000 claims 1
• 108010020346 Polyglutamic Acid Proteins 0.000 claims 1
• 229920000954 Polyglycolide Polymers 0.000 claims 1
• 229920001710 Polyorthoester Polymers 0.000 claims 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
• 241000700159 Rattus Species 0.000 claims 1
• 206010038389 Renal cancer Diseases 0.000 claims 1
• 102000000505 Ribonucleotide Reductases Human genes 0.000 claims 1
• 108010041388 Ribonucleotide Reductases Proteins 0.000 claims 1
• 206010039491 Sarcoma Diseases 0.000 claims 1
• 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
• 208000000453 Skin Neoplasms Diseases 0.000 claims 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
• 229920002472 Starch Polymers 0.000 claims 1
• 235000021355 Stearic acid Nutrition 0.000 claims 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
• 206010057644 Testis cancer Diseases 0.000 claims 1
• RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
• 229920001615 Tragacanth Polymers 0.000 claims 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
• 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
• 206010047700 Vomiting Diseases 0.000 claims 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
• GIUYCYHIANZCFB-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(6-amino-2-fluoropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O GIUYCYHIANZCFB-UUOKFMHZSA-N 0.000 claims 1
• KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 claims 1
• 238000010521 absorption reaction Methods 0.000 claims 1
• 238000009825 accumulation Methods 0.000 claims 1
• 235000011054 acetic acid Nutrition 0.000 claims 1
• 229930183665 actinomycin Natural products 0.000 claims 1
• 239000012190 activator Substances 0.000 claims 1
• 239000011149 active material Substances 0.000 claims 1
• 239000013543 active substance Substances 0.000 claims 1
• 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
• 229960005305 adenosine Drugs 0.000 claims 1
• 229940009456 adriamycin Drugs 0.000 claims 1
• 239000000443 aerosol Substances 0.000 claims 1
• 101150031426 agaC gene Proteins 0.000 claims 1
• 125000001931 aliphatic group Chemical group 0.000 claims 1
• 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
• 125000002877 alkyl aryl group Chemical group 0.000 claims 1
• 230000002152 alkylating effect Effects 0.000 claims 1
• 231100000360 alopecia Toxicity 0.000 claims 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
• 230000004075 alteration Effects 0.000 claims 1
• 229910052782 aluminium Inorganic materials 0.000 claims 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
• 229940024606 amino acid Drugs 0.000 claims 1
• 235000001014 amino acid Nutrition 0.000 claims 1
• 150000001413 amino acids Chemical class 0.000 claims 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 claims 1
• 235000011130 ammonium sulphate Nutrition 0.000 claims 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims 1
• 229960001220 amsacrine Drugs 0.000 claims 1
• 230000003698 anagen phase Effects 0.000 claims 1
• 238000010171 animal model Methods 0.000 claims 1
• 208000022531 anorexia Diseases 0.000 claims 1
• 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
• 239000002260 anti-inflammatory agent Substances 0.000 claims 1
• 230000000840 anti-viral effect Effects 0.000 claims 1
• 229940121375 antifungal agent Drugs 0.000 claims 1
• 229940034982 antineoplastic agent Drugs 0.000 claims 1
• 239000003963 antioxidant agent Substances 0.000 claims 1
• 235000006708 antioxidants Nutrition 0.000 claims 1
• 101150044616 araC gene Proteins 0.000 claims 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
• 125000000254 aspartoyl group Chemical group 0.000 claims 1
• 238000003556 assay Methods 0.000 claims 1
• 239000012298 atmosphere Substances 0.000 claims 1
• 238000000376 autoradiography Methods 0.000 claims 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
• 229910052788 barium Inorganic materials 0.000 claims 1
• DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
• 235000010233 benzoic acid Nutrition 0.000 claims 1
• 238000006480 benzoylation reaction Methods 0.000 claims 1
• 235000019445 benzyl alcohol Nutrition 0.000 claims 1
• 229920000249 biocompatible polymer Polymers 0.000 claims 1
• 229910052797 bismuth Inorganic materials 0.000 claims 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims 1
• 238000009835 boiling Methods 0.000 claims 1
• 210000001185 bone marrow Anatomy 0.000 claims 1
• 229940098773 bovine serum albumin Drugs 0.000 claims 1
• 239000012267 brine Substances 0.000 claims 1
• 230000031709 bromination Effects 0.000 claims 1
• 238000005893 bromination reaction Methods 0.000 claims 1
• UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 claims 1
• 230000005587 bubbling Effects 0.000 claims 1
• 239000000872 buffer Substances 0.000 claims 1
• DXXXHNQOKVRSES-UHFFFAOYSA-N but-2-ene-1,3-diol Chemical compound CC(O)=CCO DXXXHNQOKVRSES-UHFFFAOYSA-N 0.000 claims 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
• 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• 229910052793 cadmium Inorganic materials 0.000 claims 1
• BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims 1
• 229910052791 calcium Inorganic materials 0.000 claims 1
• 239000011575 calcium Substances 0.000 claims 1
• 239000004202 carbamide Substances 0.000 claims 1
• 229960004562 carboplatin Drugs 0.000 claims 1
• 150000001244 carboxylic acid anhydrides Chemical class 0.000 claims 1
• 150000001733 carboxylic acid esters Chemical group 0.000 claims 1
• 229960005243 carmustine Drugs 0.000 claims 1
• 150000001768 cations Chemical class 0.000 claims 1
• 230000022131 cell cycle Effects 0.000 claims 1
• 230000032823 cell division Effects 0.000 claims 1
• 230000022534 cell killing Effects 0.000 claims 1
• 230000019522 cellular metabolic process Effects 0.000 claims 1
• 230000007541 cellular toxicity Effects 0.000 claims 1
• 210000003169 central nervous system Anatomy 0.000 claims 1
• 201000007455 central nervous system cancer Diseases 0.000 claims 1
• 201000010881 cervical cancer Diseases 0.000 claims 1
• 201000010288 cervix melanoma Diseases 0.000 claims 1
• 230000008859 change Effects 0.000 claims 1
• 239000002738 chelating agent Substances 0.000 claims 1
• 239000007795 chemical reaction product Substances 0.000 claims 1
• 239000003638 chemical reducing agent Substances 0.000 claims 1
• 229940112822 chewing gum Drugs 0.000 claims 1
• 235000015218 chewing gum Nutrition 0.000 claims 1
• 238000005660 chlorination reaction Methods 0.000 claims 1
• 235000012000 cholesterol Nutrition 0.000 claims 1
• 229960001265 ciclosporin Drugs 0.000 claims 1
• 150000001860 citric acid derivatives Chemical class 0.000 claims 1
• 229910017052 cobalt Inorganic materials 0.000 claims 1
• 239000010941 cobalt Substances 0.000 claims 1
• GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims 1
• 229920001436 collagen Polymers 0.000 claims 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
• 238000001816 cooling Methods 0.000 claims 1
• 229910052802 copper Inorganic materials 0.000 claims 1
• 239000010949 copper Substances 0.000 claims 1
• 239000008120 corn starch Substances 0.000 claims 1
• 239000006071 cream Substances 0.000 claims 1
• 238000004132 cross linking Methods 0.000 claims 1
• JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 claims 1
• 229960004397 cyclophosphamide Drugs 0.000 claims 1
• 229930182912 cyclosporin Natural products 0.000 claims 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
• 230000003436 cytoskeletal effect Effects 0.000 claims 1
• 231100000433 cytotoxic Toxicity 0.000 claims 1
• 230000001472 cytotoxic effect Effects 0.000 claims 1
• 230000003013 cytotoxicity Effects 0.000 claims 1
• 231100000135 cytotoxicity Toxicity 0.000 claims 1
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims 1
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 claims 1
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 claims 1
• GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 claims 1
• 230000009615 deamination Effects 0.000 claims 1
• 238000006481 deamination reaction Methods 0.000 claims 1
• 230000034994 death Effects 0.000 claims 1
• 238000007360 debenzoylation reaction Methods 0.000 claims 1
• 230000007423 decrease Effects 0.000 claims 1
• 206010061428 decreased appetite Diseases 0.000 claims 1
• 230000003247 decreasing effect Effects 0.000 claims 1
• 239000003405 delayed action preparation Substances 0.000 claims 1
• 238000010511 deprotection reaction Methods 0.000 claims 1
• 239000008121 dextrose Substances 0.000 claims 1
• 238000010586 diagram Methods 0.000 claims 1
• 150000004985 diamines Chemical class 0.000 claims 1
• DAKIDYQCFJQMDF-UHFFFAOYSA-N dichloromethane;pyridine Chemical compound ClCCl.C1=CC=NC=C1 DAKIDYQCFJQMDF-UHFFFAOYSA-N 0.000 claims 1
• 150000005690 diesters Chemical class 0.000 claims 1
• 239000002270 dispersing agent Substances 0.000 claims 1
• 238000009826 distribution Methods 0.000 claims 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims 1
• 231100000673 dose–response relationship Toxicity 0.000 claims 1
• 238000001035 drying Methods 0.000 claims 1
• 230000002255 enzymatic effect Effects 0.000 claims 1
• 239000002532 enzyme inhibitor Substances 0.000 claims 1
• JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims 1
• 125000004185 ester group Chemical group 0.000 claims 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
• 239000005038 ethylene vinyl acetate Substances 0.000 claims 1
• 235000019634 flavors Nutrition 0.000 claims 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
• 229960005304 fludarabine phosphate Drugs 0.000 claims 1
• 125000001153 fluoro group Chemical group F* 0.000 claims 1
• 235000013355 food flavoring agent Nutrition 0.000 claims 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
• 230000002496 gastric effect Effects 0.000 claims 1
• 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
• 238000012239 gene modification Methods 0.000 claims 1
• 230000005017 genetic modification Effects 0.000 claims 1
• 235000013617 genetically modified food Nutrition 0.000 claims 1
• 230000000762 glandular Effects 0.000 claims 1
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
• 235000011187 glycerol Nutrition 0.000 claims 1
• 229940093915 gynecological organic acid Drugs 0.000 claims 1
• 208000024963 hair loss Diseases 0.000 claims 1
• 230000003676 hair loss Effects 0.000 claims 1
• 150000004820 halides Chemical class 0.000 claims 1
• 229910052736 halogen Inorganic materials 0.000 claims 1
• 230000002140 halogenating effect Effects 0.000 claims 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
• 210000003494 hepatocyte Anatomy 0.000 claims 1
• 235000001050 hortel pimenta Nutrition 0.000 claims 1
• 230000007062 hydrolysis Effects 0.000 claims 1
• 238000006460 hydrolysis reaction Methods 0.000 claims 1
• 239000007943 implant Substances 0.000 claims 1
• 238000002513 implantation Methods 0.000 claims 1
• 238000011065 in-situ storage Methods 0.000 claims 1
• 230000002779 inactivation Effects 0.000 claims 1
• 238000010348 incorporation Methods 0.000 claims 1
• 239000003701 inert diluent Substances 0.000 claims 1
• 239000004615 ingredient Substances 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 claims 1
• 239000002054 inoculum Substances 0.000 claims 1
• 229960003786 inosine Drugs 0.000 claims 1
• 230000008611 intercellular interaction Effects 0.000 claims 1
• 238000010253 intravenous injection Methods 0.000 claims 1
• 230000002427 irreversible effect Effects 0.000 claims 1
• 238000002955 isolation Methods 0.000 claims 1
• 229960000310 isoleucine Drugs 0.000 claims 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
• 201000010982 kidney cancer Diseases 0.000 claims 1
• 239000008101 lactose Substances 0.000 claims 1
• 210000002429 large intestine Anatomy 0.000 claims 1
• 201000011486 lichen planus Diseases 0.000 claims 1
• XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims 1
• 238000004811 liquid chromatography Methods 0.000 claims 1
• 239000012280 lithium aluminium hydride Substances 0.000 claims 1
• 239000000314 lubricant Substances 0.000 claims 1
• 208000003747 lymphoid leukemia Diseases 0.000 claims 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
• 239000011777 magnesium Substances 0.000 claims 1
• 229910052749 magnesium Inorganic materials 0.000 claims 1
• 235000019359 magnesium stearate Nutrition 0.000 claims 1
• 239000001630 malic acid Substances 0.000 claims 1
• 235000011090 malic acid Nutrition 0.000 claims 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
• 231100000682 maximum tolerated dose Toxicity 0.000 claims 1
• 239000012528 membrane Substances 0.000 claims 1
• 108020004999 messenger RNA Proteins 0.000 claims 1
• 239000002207 metabolite Substances 0.000 claims 1
• LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 claims 1
• 150000002739 metals Chemical class 0.000 claims 1
• FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 claims 1
• 229930182817 methionine Natural products 0.000 claims 1
• CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 claims 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
• 239000008108 microcrystalline cellulose Substances 0.000 claims 1
• 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
• 229960004857 mitomycin Drugs 0.000 claims 1
• 150000004712 monophosphates Chemical class 0.000 claims 1
• 210000004877 mucosa Anatomy 0.000 claims 1
• 208000025113 myeloid leukemia Diseases 0.000 claims 1
• 201000000050 myeloid neoplasm Diseases 0.000 claims 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
• YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical class C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 claims 1
• PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
• 230000001338 necrotic effect Effects 0.000 claims 1
• 230000001613 neoplastic effect Effects 0.000 claims 1
• 229910017604 nitric acid Inorganic materials 0.000 claims 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
• 239000000346 nonvolatile oil Substances 0.000 claims 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
• 235000021313 oleic acid Nutrition 0.000 claims 1
• 150000002889 oleic acids Chemical class 0.000 claims 1
• 238000011275 oncology therapy Methods 0.000 claims 1
• 239000007968 orange flavor Substances 0.000 claims 1
• 235000005985 organic acids Nutrition 0.000 claims 1
• 150000002892 organic cations Chemical class 0.000 claims 1
• 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
• 229940127084 other anti-cancer agent Drugs 0.000 claims 1
• 235000006408 oxalic acid Nutrition 0.000 claims 1
• 238000005895 oxidative decarboxylation reaction Methods 0.000 claims 1
• 238000005949 ozonolysis reaction Methods 0.000 claims 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 1
• WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims 1
• 201000002528 pancreatic cancer Diseases 0.000 claims 1
• 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
• 230000001717 pathogenic effect Effects 0.000 claims 1
• 108040007629 peroxidase activity proteins Proteins 0.000 claims 1
• 235000021317 phosphate Nutrition 0.000 claims 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
• 230000026731 phosphorylation Effects 0.000 claims 1
• 238000006366 phosphorylation reaction Methods 0.000 claims 1
• 230000019612 pigmentation Effects 0.000 claims 1
• 230000036470 plasma concentration Effects 0.000 claims 1
• 239000004033 plastic Substances 0.000 claims 1
• 229920003023 plastic Polymers 0.000 claims 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 1
• 229920000747 poly(lactic acid) Polymers 0.000 claims 1
• 229920002401 polyacrylamide Polymers 0.000 claims 1
• 229920001223 polyethylene glycol Polymers 0.000 claims 1
• 229920002643 polyglutamic acid Polymers 0.000 claims 1
• 239000004633 polyglycolic acid Substances 0.000 claims 1
• 239000004626 polylactic acid Substances 0.000 claims 1
• 239000011591 potassium Substances 0.000 claims 1
• 229910052700 potassium Inorganic materials 0.000 claims 1
• 239000013615 primer Substances 0.000 claims 1
• 238000012545 processing Methods 0.000 claims 1
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
• 230000001681 protective effect Effects 0.000 claims 1
• 230000009467 reduction Effects 0.000 claims 1
• 230000002441 reversible effect Effects 0.000 claims 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
• 229940081974 saccharin Drugs 0.000 claims 1
• 235000019204 saccharin Nutrition 0.000 claims 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
• 230000028327 secretion Effects 0.000 claims 1
• 238000000926 separation method Methods 0.000 claims 1
• 125000003808 silyl group Chemical class [H][Si]([H])([H])[*] 0.000 claims 1
• 229910052708 sodium Inorganic materials 0.000 claims 1
• 239000011734 sodium Substances 0.000 claims 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 1
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims 1
• 239000008107 starch Substances 0.000 claims 1
• 235000019698 starch Nutrition 0.000 claims 1
• 239000007858 starting material Substances 0.000 claims 1
• 208000003265 stomatitis Diseases 0.000 claims 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
• PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
• 150000003871 sulfonates Chemical class 0.000 claims 1
• 239000013589 supplement Substances 0.000 claims 1
• 238000003786 synthesis reaction Methods 0.000 claims 1
• 239000011975 tartaric acid Substances 0.000 claims 1
• 235000002906 tartaric acid Nutrition 0.000 claims 1
• 201000003120 testicular cancer Diseases 0.000 claims 1
• NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
• 206010043554 thrombocytopenia Diseases 0.000 claims 1
• 229940113082 thymine Drugs 0.000 claims 1
• 239000010936 titanium Substances 0.000 claims 1
• 229910052719 titanium Inorganic materials 0.000 claims 1
• XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims 1
• 238000011200 topical administration Methods 0.000 claims 1
• 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
• 231100000820 toxicity test Toxicity 0.000 claims 1
• 235000010487 tragacanth Nutrition 0.000 claims 1
• 239000000196 tragacanth Substances 0.000 claims 1
• 229940116362 tragacanth Drugs 0.000 claims 1
• 230000005030 transcription termination Effects 0.000 claims 1
• 125000001425 triazolyl group Chemical group 0.000 claims 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
• RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 claims 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
• 230000004222 uncontrolled growth Effects 0.000 claims 1
• 229940035893 uracil Drugs 0.000 claims 1
• 230000002485 urinary effect Effects 0.000 claims 1
• 206010046766 uterine cancer Diseases 0.000 claims 1
• 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• 239000003981 vehicle Substances 0.000 claims 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
• 230000008673 vomiting Effects 0.000 claims 1
• 235000012431 wafers Nutrition 0.000 claims 1
• 230000003442 weekly effect Effects 0.000 claims 1
• 230000004580 weight loss Effects 0.000 claims 1
• MJIBOYFUEIDNPI-HBNMXAOGSA-L zinc 5-[2,3-dihydroxy-5-[(2R,3R,4S,5R,6S)-4,5,6-tris[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxy]-2-[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxymethyl]oxan-3-yl]oxycarbonylphenoxy]carbonyl-3-hydroxybenzene-1,2-diolate Chemical class [Zn++].Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c([O-])c([O-])c2)c1 MJIBOYFUEIDNPI-HBNMXAOGSA-L 0.000 claims 1
• 230000000719 anti-leukaemic effect Effects 0.000 abstract description 2
• 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
• 125000004423 acyloxy group Chemical group 0.000 abstract 1
• 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
• 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
• 125000001624 naphthyl group Chemical group 0.000 abstract 1
• 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
• 239000008259 solid foam Substances 0.000 description 13
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 10
• 239000012074 organic phase Substances 0.000 description 7
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 6
• 239000012153 distilled water Substances 0.000 description 6
• 239000012300 argon atmosphere Substances 0.000 description 5
• 238000004587 chromatography analysis Methods 0.000 description 5
• 230000008878 coupling Effects 0.000 description 5
• 238000010168 coupling process Methods 0.000 description 5
• 238000005859 coupling reaction Methods 0.000 description 5
• 239000003480 eluent Substances 0.000 description 5
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
• 235000019341 magnesium sulphate Nutrition 0.000 description 5
• 230000001575 pathological effect Effects 0.000 description 5
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
• KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
• 238000010908 decantation Methods 0.000 description 4
• WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 4
• 229960004679 doxorubicin Drugs 0.000 description 4
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 4
• 229960003171 plicamycin Drugs 0.000 description 4
• 235000017557 sodium bicarbonate Nutrition 0.000 description 4
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
• 150000003462 sulfoxides Chemical class 0.000 description 4
• DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 239000008346 aqueous phase Substances 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 150000002576 ketones Chemical class 0.000 description 3
• WSDQIHATCCOMLH-UHFFFAOYSA-N phenyl n-(3,5-dichlorophenyl)carbamate Chemical compound ClC1=CC(Cl)=CC(NC(=O)OC=2C=CC=CC=2)=C1 WSDQIHATCCOMLH-UHFFFAOYSA-N 0.000 description 3
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 108090000704 Tubulin Proteins 0.000 description 2
• 102000004243 Tubulin Human genes 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 229910052783 alkali metal Inorganic materials 0.000 description 2
• 150000003927 aminopyridines Chemical class 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• 125000005110 aryl thio group Chemical group 0.000 description 2
• DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 229940098779 methanesulfonic acid Drugs 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 239000002808 molecular sieve Substances 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 229910052710 silicon Inorganic materials 0.000 description 2
• 239000010703 silicon Substances 0.000 description 2
• 239000000377 silicon dioxide Substances 0.000 description 2
• 238000006884 silylation reaction Methods 0.000 description 2
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
• 229940063683 taxotere Drugs 0.000 description 2
• NTJBWZHVSJNKAD-UHFFFAOYSA-N triethylazanium;fluoride Chemical compound [F-].CC[NH+](CC)CC NTJBWZHVSJNKAD-UHFFFAOYSA-N 0.000 description 2
• ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
• UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• 101150084750 1 gene Proteins 0.000 description 1
• KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical compound C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 description 1
• CPEONABTMRSIKA-UHFFFAOYSA-N 1,4$l^{2}-oxazinane Chemical compound C1COCC[N]1 CPEONABTMRSIKA-UHFFFAOYSA-N 0.000 description 1
• DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
• KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical class CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
• GTEBGKZZGCBLNT-RVWNTZLHSA-N CC(O)=O.C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC)[C@H](C(C)=O)[C@@]1(C)CC2 Chemical compound CC(O)=O.C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC)[C@H](C(C)=O)[C@@]1(C)CC2 GTEBGKZZGCBLNT-RVWNTZLHSA-N 0.000 description 1
• FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 239000005662 Paraffin oil Substances 0.000 description 1
• YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
• 229910018557 Si O Inorganic materials 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
• 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
• 150000008046 alkali metal hydrides Chemical class 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
• 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 125000005129 aryl carbonyl group Chemical group 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 125000006630 butoxycarbonylamino group Chemical group 0.000 description 1
• 235000013877 carbamide Nutrition 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 150000001723 carbon free-radicals Chemical class 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 239000012050 conventional carrier Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 230000021953 cytokinesis Effects 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 229960000452 diethylstilbestrol Drugs 0.000 description 1
• 210000002249 digestive system Anatomy 0.000 description 1
• 150000004656 dimethylamines Chemical class 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
• 150000002224 folic acids Chemical class 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 238000007306 functionalization reaction Methods 0.000 description 1
• 210000004392 genitalia Anatomy 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229960002899 hydroxyprogesterone Drugs 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
• 229940011051 isopropyl acetate Drugs 0.000 description 1
• GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 229960000350 mitotane Drugs 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 description 1
• 239000012429 reaction media Substances 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 150000003281 rhenium Chemical class 0.000 description 1
• 229960003440 semustine Drugs 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Inorganic materials [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 229910000104 sodium hydride Inorganic materials 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 201000000498 stomach carcinoma Diseases 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 150000003510 tertiary aliphatic amines Chemical class 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 150000003918 triazines Chemical class 0.000 description 1
• 125000004953 trihalomethyl group Chemical group 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 150000003672 ureas Chemical class 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• HOFQVRTUGATRFI-XQKSVPLYSA-N vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
• 239000008096 xylene Substances 0.000 description 1
• 150000003738 xylenes Chemical class 0.000 description 1